Search Results for "meloxicam"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for meloxicam. Results 1 to 5 of 5 total matches.
See also: Mobic

IV Meloxicam (Anjeso) for Pain

   
The Medical Letter on Drugs and Therapeutics • Jun 29, 2020  (Issue 1601)
IV Meloxicam (Anjeso) for Pain ...
The FDA has approved Anjeso (Baudax Bio), an IV formulation of the nonsteroidal anti-inflammatory drug (NSAID) meloxicam, for once-daily treatment of moderate to severe pain in adults. Oral meloxicam (Mobic, and others), which is only indicated for treatment of chronic pain associated with osteoarthritis or rheumatoid arthritis, has been available for 20 years. IV formulations of ketorolac, ibuprofen (Caldolor), and acetaminophen (Ofirmev) are also available for treatment of pain.
Med Lett Drugs Ther. 2020 Jun 29;62(1601):100-2 |  Show IntroductionHide Introduction

Bupivacaine/Meloxicam (Zynrelef) for Postsurgical Pain

   
The Medical Letter on Drugs and Therapeutics • Jan 24, 2022  (Issue 1642)
Bupivacaine/Meloxicam (Zynrelef) for Postsurgical Pain ...
The FDA has approved a fixed-dose combination of the amide local anesthetic bupivacaine and the nonsteroidal anti-inflammatory drug (NSAID) meloxicam as an extended-release (ER) solution (Zynrelef – Heron) for single-dose, intraoperative, soft-tissue or periarticular instillation to provide postsurgical analgesia for up to 72 hours in adults undergoing foot and ankle, small-to-medium open abdominal, or lower extremity total joint arthroplasty surgical procedures.
Med Lett Drugs Ther. 2022 Jan 24;64(1642):13-5 |  Show IntroductionHide Introduction

A Fixed-Dose Combination of Meloxicam and Rizatriptan (Symbravo) for Migraine

   
The Medical Letter on Drugs and Therapeutics • Apr 28, 2025  (Issue 1727)
A Fixed-Dose Combination of Meloxicam and Rizatriptan (Symbravo) for Migraine ...
The FDA has approved Symbravo (Axsome), an oral fixed-dose combination of the nonsteroidal anti-inflammatory drug (NSAID) meloxicam and the 5-HT1B/1D receptor agonist (triptan) rizatriptan (Maxalt, and generics), for acute treatment of migraine with or without aura in adults. It is the second combination of an NSAID and a triptan to be approved for migraine treatment. An oral fixed-dose combination of sumatriptan and naproxen (Treximet, and generics) is approved for use in patients ≥12 years old.
Med Lett Drugs Ther. 2025 Apr 28;67(1727):68-70   doi:10.58347/tml.2025.1727b |  Show IntroductionHide Introduction

Comparison Table: Some Nonopioid Analgesics for Pain (online only)

   
The Medical Letter on Drugs and Therapeutics • Mar 07, 2022  (Issue 1645)
interfere with platelet function and prolong bleeding time (less likely with meloxicam or nabumetone ...
View the Comparison Table: Some Nonopioid Analgesics for Pain
Med Lett Drugs Ther. 2022 Mar 7;64(1645):e40-3 |  Show IntroductionHide Introduction

Nonopioid Drugs for Pain

   
The Medical Letter on Drugs and Therapeutics • Mar 07, 2022  (Issue 1645)
) in dysmenorrhea Meloxicam – generic 7.5, 15 mg tabs; 7.5-15 mg once/day Appears to be more selective 0.30 7.5 mg ...
Nonopioid drugs can be used in the treatment of many nociceptive and neuropathic pain conditions. For severe pain, especially severe chronic cancer pain, use of opioids may be necessary. Noninvasive nonpharmacologic treatments, including physical and psychological therapies, have been shown to improve pain and function in patients with some common chronic pain conditions and are unlikely to cause serious harms. A multimodal approach to analgesic therapy can increase pain control while reducing opioid use and adverse effects.
Med Lett Drugs Ther. 2022 Mar 7;64(1645):33-40 |  Show IntroductionHide Introduction